Blood Res.  2019 Jun;54(2):153-156. 10.5045/br.2019.54.2.153.

What is the most appropriate regimen for untreated Waldenström macroglobulinemia? - An updated analysis of rituximab and half-dose CHOP therapy and cost effectiveness

• Sekiguchi
• Hamano A
• Kitagawa T
• Ito K
• Hirano K
• Yamada K

• KMID: 2451019
• DOI: http://doi.org/10.5045/br.2019.54.2.153

Abstract

No abstract available.

MeSH Terms

Cost-Benefit Analysis*
Rituximab*
Waldenstrom Macroglobulinemia*
Rituximab

Figure

• 

  Fig. 1 Survival curve. (A) Progression-free survival (PFS). The median PFS of half-dose R-CHOP therapy was not reached, and the estimated 2-year PFS was 72% and 3-year PFS was 64%. The estimated 3-year second PFS by a bendamustine-containing regimen was 89%. (B) Overall survival (OS). The estimated 3-year OS was 96%.

• 

  Fig. 2 Swimmer plot for 25 patients who received half-dose R-CHOP therapy. Nine patients developed refractory disease or progression and 3 patients received third-line therapy.

Reference

1. Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med. 2012; 367:826–833.

2. Sekiguchi N, Nomoto J, Nagata A, et al. Gene expression profile signature of aggressive Waldenström macroglobulinemia with chromosome 6q deletion. Biomed Res Int. 2018; 2018:6728128.

3. Sekiguchi N, Hamano A, Kitagawa T, et al. Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic Waldenström Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent. Blood Res. 2018; 53:117–122.

4. Buske C, Hoster E, Dreyling M, et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia. 2009; 23:153–161.

5. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013; 381:1203–1210.

6. Buske C, Sadullah S, Kastritis E, et al. Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review. Lancet Haematol. 2018; 5:e299–e309.

7. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol. 2007; 25:3344–3349.

8. Olszewski AJ, Treon SP, Castillo JJ. Application and outcomes of bendamustine- or bortezomib-based therapy for Waldenstrom's macroglobulinemia. Blood (ASH Annual Meeting Abstracts). 2017; 130:Suppl. abst 348.

9. Lee HS, Kim K, Yoon DH, et al. Clinical factors associated with response or survival after chemotherapy in patients with Waldenström macroglobulinemia in Korea. Biomed Res Int. 2014; 2014:253243.

10. Saito A, Isoda A, Kojima M, et al. Retrospective analysis of prognostic factors for WaldenstrXMLLink_XYZm macroglobulinemia: a multicenter cooperative study in Japan. Int J Hematol. 2017; 106:681–690.

11. Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009; 27:3830–3835.

12. Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med. 2015; 372:1430–1440.

13. Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenström's macroglobulinemia. N Engl J Med. 2018; 378:2399–2410.

14. Olszewski AJ, Castillo JJ. Ibrutinib and rituximab in Waldenström's macroglobulinemia. N Engl J Med. 2018; 379:1973–1974.

15. Aiello A, D'Ausilio A, Lo Muto R, Randon F, Laurenti L. Cost-effectiveness analysis of ibrutinib in patients with Waldenström macroglobulinemia in Italy. J Mark Access Health Policy. 2017; 5:1393308.